Browse Studies — Arctuva

Phase 3

An Open-Label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients With Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/Week and 120 mg/kg/Week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)

This study is designed to compare two different weekly doses of a medicine called Alpha1-Proteinase Inhibitor given by injection under the skin with the standa…

Alpha 1 Antitrypsin Deficiency

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Find your next paid study

Alpha-1 Foundation DNA and Tissue Bank